Precision Medicine Podcast · Trapelo

Advancing Prostate Cancer Care with Dr. William Oh: Precision Medicine, Diagnostics and Advocacy (Part 2)

·33 min·5 clips
The episode continues a broader focus on prostate cancer with Dr. William Oh, who returns for a second conversation after part one covered the disease’s rising burden and the screening landscape. Karen Cushman sets up the discussion around the clinical and practical problems oncologists, reference labs, and payers face as precision medicine expands. Dr. Oh explains why prostate cancers often do not respond to immunotherapy as well as some other cancers. He notes that prostate tumors tend not to be very mutated, which makes them weaker candidates for immune-based treatment. The conversation makes clear that the field is still trying to turn so-called cold tumors into hot ones. That effort includes vaccines and additional checkpoint inhibitors that might help the immune system recognize and attack the cancer more effectively. Karen presses on the question of whether combination treatment is becoming the more realistic path forward. Dr. Oh agrees that combinations are likely the future. He points out that only about one or two percent of patients are candidates for pembrolizumab as a single agent. Those patients tend to have TMB-high or MSI-high tumors. The episode stresses that this is uncommon, but also that it is important to test for it. When those markers are present, the chance of response can be meaningful. The discussion then widens to the broader treatment landscape. Dr. Oh suggests that immunotherapy will likely need to be paired with other approaches. He mentions traditional androgen receptor drugs as part of that evolving mix. He also points toward cancer vaccines and other checkpoint inhibitors as promising partners. Throughout, the show stays attentive to the gap between what is exciting in theory and what is available in practice. The tone remains careful rather than promotional. The conversation keeps returning to how patients experience these decisions, not just how researchers describe them. Dr. Oh also speaks from his position as director of precision medicine at Yale Cancer Center and as chair of the American Cancer Society National Prostate Cancer Roundtable. That gives the discussion both a research and advocacy lens. The episode ends by opening out toward the next phase of targeted treatment development. It leaves the listener with the sense that prostate cancer care is changing, but unevenly and with a lot still unresolved. The show uses that uncertainty to sharpen, not flatten, the medical context.

As heard by us

A measured look at prostate cancer precision medicine, with promise ahead but few easy answers.

The episode takes a careful, practical look at prostate cancer care, with Dr. William Oh explaining why immunotherapy has fallen short so far and why only about one or two percent of patients are candidates for pembrolizumab as a single agent.

Read the full review in PlayNext →

Why you'd press play

Want a clear read on where prostate cancer precision medicine is helping, and where it still falls short?

Read the full recommendation in PlayNext →
Listen to the show on